socalTECH

MAY 16, 2011

Pasadena-based venture capital firm Arcturus Capital has scored an exit out of its portfolio this morning, as Milpitas, California-based Pliant Technology was acquired by SanDisk in a deal worth $327M. SanDisk said it would pay $327M in cash, plus equity-based incentives for Pliant, a developer of enterprise solid state disk drives (SSDs).

Arcturus 150

Arcturus Pasadena Venture Capital Equity 150

socalTECH

MAY 16, 2014

TrueCar is venture backed by backed by USAA, Capricorn Investment Group, Upfront Ventures, Anthem Ventures, Vulcan Capital Growth Equity, Peppy Capital Partners, Arcturus Venture Capital, along with others. TrueCar is trading on the NASDAQ Global Select Market as TRUE. READ MORE>>. truecar true buying service scott painter'

Truecar 147

Truecar Pricing Arcturus Anthem 147

socalTECH

JANUARY 12, 2011

The round was led by Prospector Equity Capital and Arcturus Capital, and also included the Pasadena Angels and Tech Coast Angels. Monrovia-based Ondax , a manufacturer of volume holographic grating filters and lasers, said Tuesday that it has officially closed its $2.2M, Series E funding round.

Tech Coast Angels 133

Tech Coast Angels Arcturus Pasadena Angels Monrovia 133

socalTECH

JANUARY 15, 2010

ONDAX is backed by Arcturus Capital, Prospector Equity Capital, and others. Moser is a native of Switzerland, and will remain as Chief Technology Officer at the firm. Heyler was most recently at Newport Corporation.

Arcturus 124

Arcturus Chief Technology Officer Monrovia Equity 124

socalTECH

JUNE 19, 2009

in an equity funding round, according to a regulatory filing by the firm yesterday. Dr. Schuh was previously CEO and Director of AviaraDx, and also served at Arcturus Bioscience and Sequenom. San Diego-based Sorrento Therapeutics , a new biotechnology startup, has raised $2.3M Source of the funding was not disclosed.

Arcturus 100

Arcturus San Diego Venture Capital Equity 100

Xconomy

APRIL 17, 2020

The public markets are moving erratically, but Alnylam Pharmaceuticals showed this week that selling equity isn’t the only way for biotech companies to raise cash. Late last year Alnylam (NASDAQ: ALNY ) began exploring potential royalty deals for inclisiran, a drug that uses RNA interference to lower cholesterol.

Equity 84

Equity Activity Marketing Company 84